Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsAxicorp

    Axicorp

    Jump to

    • Espirito Santo questions Biocon's accounting practices

      Espirito Santo has downgraded Bangalore-based Biocon to "sell" from "neutral" and sharply revised its target price to Rs 186 a share from Rs 350, flagging off several issues, which it says raise accounting and corporate governance questions over at the biotech firm.

    • Biocon Q2 net drops as energy costs, wages rise

      Biocon Ltd, India top biotechnology company, reported a 4% drop in quarterly profit due to higher energy costs and rise in wages, but said strong demand from branded formulations offered opportunities for growth.

    • Biocon Q1 net down 9% to Rs 70 crore, shares fall

      Biotechnology company Biocon's consolidated net profit for the first quarter fell almost 9% from a year ago to Rs 70.05 crore, while net sales were up over 10% to Rs 441.68 crore.

    • Pfizer partnership to give Biocon strong foothold in Europe

      This quarter Biocon's net profit has risen 25% from the same period last year to 101 crore rupees, meeting analyst estimates and to keep this growth going, Biocon is shedding the fat, reports CNBC-TV18's Vineetha Athrey.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347